nach oben

Erschienen in:

01.05.2007 | Article

Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men

verfasst von: H. B. Holt, S. H. Wild, A. D. Postle, J. Zhang, G. Koster, M. Umpleby, F. Shojaee-Moradie, K. Dewbury, P. J. Wood, D. I. Phillips, C. D. Byrne

Erschienen in: Diabetologia | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The regulation of cortisol metabolism in vivo is not well understood. We evaluated the relationship between cortisol metabolism and insulin sensitivity, adjusting for total and regional fat content and for non-alcoholic fatty liver disease.

Materials and methods

Twenty-nine middle-aged healthy men with a wide range of BMI were recruited. We measured fat content by dual-energy X-ray absorptiometry and magnetic resonance imaging (MRI), liver fat by ultrasound and MRI, the hypothalamic-pituitary-adrenal axis by adrenal response to ACTH_1-24, unconjugated urinary cortisol excretion, corticosteroid-binding globulin, and cortisol clearance by MS. We assessed insulin sensitivity by hyperinsulinaemic-euglycaemic clamp and by OGTT.

Results

Cortisol clearance was strongly inversely correlated with insulin sensitivity (M value) (r = −0.61, p = 0.002). Cortisol clearance was increased in people with fatty liver compared with those without (mean±SD: 243 ± 10 vs 158 ± 36 ml/min; p = 0.014). Multiple regression modelling showed that the relationship between cortisol clearance and insulin sensitivity was independent of body fat. The relationship between fatty liver and insulin sensitivity was significantly influenced by body fat and cortisol clearance.

Conclusions/interpretation

Cortisol clearance is strongly associated with insulin sensitivity, independently of the amount of body fat. The relationship between fatty liver and insulin sensitivity is mediated in part by both fatness and cortisol clearance.

Nur mit Berechtigung zugänglich

Strain GW, Zumoff B, Kream J, Strain JJ, Levin J, Fukushima D (1982) Sex difference in the influence of obesity on the 24 hr mean plasma concentration of cortisol. Metabolism 31:209–212PubMedCrossRef

Jessop DS, Dallman MF, Fleming D, Lightman SL (2001) Resistance to glucocorticoid feedback in obesity. J Clin Endocrinol Metab 86:4109–4114PubMedCrossRef

Purnell JQ, Brandon DD, Isabelle LM, Loriaux DL, Samuels MH (2004) Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab 89:281–287PubMedCrossRef

Andrew R, Phillips DI, Walker BR (1998) Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 83:1806–1809PubMedCrossRef

Lottenberg SA, Giannella-Neto D, Derendorf H et al (1998) Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int J Clin Pharmacol Ther 36:501–505PubMed

Reynolds RM, Walker BR, Syddall HE et al (2001) Altered control of cortisol secretion in adult men with low birth weight and cardiovascular risk factors. J Clin Endocrinol Metab 86:245–250PubMedCrossRef

Walker BR, Soderberg S, Lindahl B, Olsson T (2000) Independent effects of obesity and cortisol in predicting cardiovascular risk factors in men and women. J Intern Med 247:198–204PubMedCrossRef

Ahmed MH, Byrne CD (2005) Non alcoholic steatohepatitis. In: Byrne CD, Wild SH (eds) The metabolic syndrome, 1st edn. Wiley, Chichester, pp 279–303

Angulo P (2002) Nonalcoholic fatty liver disease. N Engl J Med 346:1221–1231PubMedCrossRef

10.

Holt HB, Wild SH, Wood PJ et al (2006) Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia 49:141–148PubMedCrossRef

11.

Utzschneider KM, Kahn SE (2006) The role of insulin resistance in non-alcoholic fatty liver disease. J Clin Endocrinol Metab 91:4753–4761PubMedCrossRef

12.

Zoppini G, Targher G, Venturi C, Zamboni C, Muggeo M (2004) Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals. Clin Endocrinol (Oxf) 61:711–715CrossRef

13.

Saruc M, Yuceyar H, Ayhan S, Turkel N, Tuzcuoglu I, Can M (2003) The association of dehydroepiandrosterone, obesity, waist-hip ratio and insulin resistance with fatty liver in postmenopausal women—a hyperinsulinemic euglycemic insulin clamp study. Hepatogastroenterology 50:771–774PubMed

14.

Westerbacka J, Yki-Jarvinen H, Vehkavaara S et al (2003) Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. J Clin Endocrinol Metab 88:4924–4931PubMedCrossRef

15.

Targher G, Bertolini L, Rodella S, Zoppini G, Zenari L, Falezza G (2006) Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 64:337–341CrossRef

16.

DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed

17.

Powrie JK, Smith GD, Hennessy TR et al (1992) Incomplete suppression of hepatic glucose production in non-insulin dependent diabetes mellitus measured with [6,6-2H2]glucose enriched glucose infusion during hyperinsulinaemic-euglycaemic clamps. Eur J Clin Invest 22:244–253CrossRef

18.

Finegood DT, Bergman RN (1983) Optimal segments: a method for smoothing tracer data to calculate metabolic fluxes. Am J Physiol 244:E472–E479PubMed

19.

Steele R (1959) Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420–430PubMedCrossRef

20.

Finegood DT, Bergman RN, Vranic M (1988) Modeling error and apparent isotope discrimination confound estimation of endogenous glucose production during euglycemic glucose clamps. Diabetes 37:1025–1034PubMedCrossRef

21.

Belfiore F, Iannello S, Volpicelli G (1998) Insulin sensitivity indices calculated from basal and OGTT-induced insulin, glucose, and FFA levels. Mol Genet Metab 63:134–141PubMedCrossRef

22.

Moore A, Aitken R, Burke C et al (1985) Cortisol assays: guidelines for the provision of a clinical biochemistry service. Ann Clin Biochem 22:435–454PubMed

23.

Jerjes WK, Cleare AJ, Peters TJ, Taylor NF (2006) Circadian rhythm of urinary steroid metabolites. Ann Clin Biochem 43:287–294PubMedCrossRef

24.

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461–470PubMed

25.

Bright GM (1995) Corticosteroid-binding globulin influences kinetic parameters of plasma cortisol transport and clearance. J Clin Endocrinol Metab 80:770–775PubMedCrossRef

26.

Tait JF (1963) Review: the use of isotopic steroids for the measurement of production rates in vivo. J Clin Endocrinol Metab 23:1285–1297PubMedCrossRef

27.

Kleinbaum D, Kupper L, Muller K, Nizam A (1998) Multiple regression analysis: general considerations. In: Applied regression analysis and other multivariate methods. Duxberry, Pacific Grove, CA, pp 237–245

28.

Clasey JL, Bouchard C, Teates CD et al (1999) The use of anthropometric and dual-energy X-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women. Obes Res 7:256–264PubMed

29.

Aldhahi W, Mun E, Goldfine AB (2004) Portal and peripheral cortisol levels in obese humans. Diabetologia 47:833–836PubMedCrossRef

30.

Saverymuttu SH, Joseph AE, Maxwell JD (1986) Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 292:13–15CrossRef

31.

Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G (2005) Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled type 2 diabetic patients. Diabet Med 22:1146–1150PubMedCrossRef

32.

Pasquali R, Ambrosi B, Armanini D et al (2002) Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose–response study. J Clin Endocrinol Metab 87:166–175PubMedCrossRef

33.

Cassidy F, Ritchie JC, Verghese K, Carroll BJ (2000) Dexamethasone metabolism in dexamethasone suppression test suppressors and nonsuppressors. Biol Psychiatry 47:677–680PubMedCrossRef

34.

Tsuei SE, Moore RG, Ashley JJ, McBride WG (1979) Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults. J Pharmacokinet Biopharm 7:249–264PubMedCrossRef

35.

Huizenga NA, Koper JW, de Lange P et al (1998) Interperson variability but intraperson stability of baseline plasma cortisol concentrations, and its relation to feedback sensitivity of the hypothalamo-pituitary-adrenal axis to a low dose of dexamethasone in elderly individuals. J Clin Endocrinol Metab 83:47–54PubMedCrossRef

36.

Kutemeyer S, Schurmeyer TH, von zur Muhlen A (1994) Effect of liver damage on the pharmacokinetics of dexamethasone. Eur J Endocrinol 131:594–597PubMed

37.

Lewis JG, Shand BI, Elder PA, Scott RS (2004) Plasma sex hormone-binding globulin rather than corticosteroid-binding globulin is a marker of insulin resistance in obese adult males. Diabetes Obes Metab 6:259–263PubMedCrossRef

38.

Fernandez-Real JM, Pugeat M, Grasa M et al (2002) Serum corticosteroid-binding globulin concentration and insulin resistance syndrome: a population study. J Clin Endocrinol Metab 87:4686–4690PubMedCrossRef

39.

Fernandez-Real JM, Pugeat M, Lopez-Bermejo A, Bornet H, Ricart W (2005) Corticosteroid-binding globulin affects the relationship between circulating adiponectin and cortisol in men and women. Metabolism 54:584–589PubMedCrossRef

40.

Wake DJ, Walker BR (2006) Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity. Endocrine 29:101–108PubMedCrossRef

41.

Whorwood CB, Donovan SJ, Wood PJ, Phillips DI (2001) Regulation of glucocorticoid receptor alpha and beta isoforms and type I 11beta-hydroxysteroid dehydrogenase expression in human skeletal muscle cells: a key role in the pathogenesis of insulin resistance? J Clin Endocrinol Metab 86:2296–2308PubMedCrossRef

42.

Reynolds RM, Chapman KE, Seckl JR, Walker BR, McKeigue PM, Lithell HO (2002) Skeletal muscle glucocorticoid receptor density and insulin resistance. JAMA 287:2505–2506PubMedCrossRef

43.

Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD (2002) Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 51:1066–1075PubMedCrossRef

44.

Reynolds RM, Fischbacher C, Bhopal R et al (2006) Differences in cortisol concentrations in South Asian and European men living in the United Kingdom. Clin Endocrinol (Oxf) 64:530–534CrossRef

45.

Bjorntorp P, Holm G, Rosmond R (1999) Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus. Diabet Med 16:373–383PubMedCrossRef

Titel: Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men
verfasst von: H. B. Holt
S. H. Wild
A. D. Postle
J. Zhang
G. Koster
M. Umpleby
F. Shojaee-Moradie
K. Dewbury
P. J. Wood
D. I. Phillips
C. D. Byrne
Publikationsdatum: 01.05.2007
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 5/2007
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-007-0629-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Aims/hypothesis

Materials and methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2007

What is the scale of the future diabetes epidemic, and how certain are we about it?

Prospective prediction of spontaneous but not recurrent autoimmune diabetes in the non-obese diabetic mouse

Association of glucose levels and glucose variability with mood in type 1 diabetic patients

Global profiling of genes modified by endoplasmic reticulum stress in pancreatic beta cells reveals the early degradation of insulin mRNAs

Improved survival rate in patients with diabetes and end-stage renal disease in Denmark